Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 2
2010 3
2011 1
2012 1
2013 1
2015 1
2016 4
2017 3
2018 4
2019 8
2020 9
2021 7
2022 6
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the ATR-CHK1 Axis in Cancer Therapy.
Rundle S, Bradbury A, Drew Y, Curtin NJ. Rundle S, et al. Among authors: drew y. Cancers (Basel). 2017 Apr 27;9(5):41. doi: 10.3390/cancers9050041. Cancers (Basel). 2017. PMID: 28448462 Free PMC article. Review.
Homologous recombination deficiency and ovarian cancer.
Ledermann JA, Drew Y, Kristeleit RS. Ledermann JA, et al. Among authors: drew y. Eur J Cancer. 2016 Jun;60:49-58. doi: 10.1016/j.ejca.2016.03.005. Epub 2016 Apr 9. Eur J Cancer. 2016. PMID: 27065456 Review.
Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.
Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Machiels JP, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL. Hong DS, et al. Among authors: drew y. Clin Cancer Res. 2020 Mar 15;26(6):1220-1228. doi: 10.1158/1078-0432.CCR-19-2962. Epub 2019 Dec 3. Clin Cancer Res. 2020. PMID: 31796521 Clinical Trial.
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Drew Y, et al. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249. Clin Cancer Res. 2024. PMID: 37939124 Free PMC article. Clinical Trial.
Emerging treatment options for ovarian cancer: focus on rucaparib.
Mariappan L, Jiang XY, Jackson J, Drew Y. Mariappan L, et al. Among authors: drew y. Int J Womens Health. 2017 Dec 15;9:913-924. doi: 10.2147/IJWH.S151194. eCollection 2017. Int J Womens Health. 2017. PMID: 29290694 Free PMC article. Review.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Kristeleit RS, Drew Y, Oza AM, Domchek SM, Banerjee S, Glasspool RM, Balmaña J, Chen LM, Patel MR, Burris HA, Safra T, Borrow J, Lin KK, Goble S, Maloney L, Shapira-Frommer R. Kristeleit RS, et al. Among authors: drew y. Br J Cancer. 2023 Jan;128(2):255-265. doi: 10.1038/s41416-022-02022-y. Epub 2022 Dec 8. Br J Cancer. 2023. PMID: 36482193 Free PMC article. Clinical Trial.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Yap TA, Kristeleit R, Michalarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodrigues DN, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Yap TA, et al. Among authors: drew y. Cancer Discov. 2020 Oct;10(10):1528-1543. doi: 10.1158/2159-8290.CD-20-0163. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532747 Free PMC article. Clinical Trial.
43 results